ArticleFrontiers in medicine2026
Efficacy and safety of ceftazidime-avibactam versus tigecycline in the treatment of pneumonia caused by carbapenem-resistant
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: A total of 63 patients with CRKP pulmonary infection admitted to Shaanxi Provincial People's Hospital from January 2023 to May 2025 were retrospectively enrolled. Patients were divided into the CAZ-AVI-based regimen group ( Results: No statistically significant differences in baseline clinical characteristics were observed between groups ( Conclusions: In this exploratory retrospective cohort, CAZ-AVI-based regimens were associated with a higher bacterial clearance rate and a lower incidence of coagulation and platelet abnormalities, while no statistically significant differences were observed in clinical efficacy or survival outcomes between the two regimens. Advanced age and comorbid diabetes mellitus showed exploratory associations with increased all-cause mortality, which warrant attention in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.